Inhibikase Therapeutics Inc (NASDAQ:IKT)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.18. At the close of trading, the stock’s price was $3.28, to imply an increase of 20.15% or $0.55 in intraday trading. The IKT share’s 52-week high remains $3.82, putting it -16.46% down since that peak but still an impressive 68.6% since price per share fell to its 52-week low of $1.03. The company has a valuation of $220.40M, with an average of 0.2 million shares in intraday trading volume over the past 10 days and average of 515.08K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Inhibikase Therapeutics Inc (IKT), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give IKT a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy.
Inhibikase Therapeutics Inc (NASDAQ:IKT) trade information
After registering a 20.15% upside in the last session, Inhibikase Therapeutics Inc (IKT) has traded red over the past five days. The 5-day price performance for the stock is 12.33%, and 21.93% over 30 days. With these gigs, the year-to-date price performance is 158.27%. Short interest in Inhibikase Therapeutics Inc (NASDAQ:IKT) saw shorts transact 0.19 million shares and set a 0.17 days time to cover.
The extremes give us $5 and $8 for target low and target high price respectively. As such, IKT has been trading -143.9% off suggested target high and -52.44% from its likely low.
Inhibikase Therapeutics Inc (IKT) estimates and forecasts
Looking at statistics comparing Inhibikase Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Inhibikase Therapeutics Inc (IKT) shares are 94.08% up over the last 6 months, with its year-to-date growth rate higher than industry average at 72.83% against 16.60%.
IKT Dividends
Inhibikase Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Inhibikase Therapeutics Inc (NASDAQ:IKT)’s Major holders
Inhibikase Therapeutics Inc insiders hold 10.46% of total outstanding shares, with institutional holders owning 11.62% of the shares at 12.98% float percentage. In total, 11.62% institutions holds shares in the company.
